Trial Profile

A Phase 3 trial of Once-daily NE3107 formulation of mild to moderate Alzheimer's Disease

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 28 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

23 Oct 2024 According to a BioVie media release, the company initiating a Phase 3 trial for AD in late 2025 with a new once-daily formulation of bezisterim.
14 Mar 2024 New trial record
11 Mar 2024 According to a BioVie media release, the company to initiate this mild- to moderate-AD in early 2025 to take advantage of progress with a once-daily (QD) formulation of NE3107. The new QD formulation is expected to be ready in early-to-mid 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com